Transplantation, AutologousHematopoietic Stem Cell TransplantationTransplantation, HomologousTransplantation ConditioningGraft vs Host DiseaseStem Cell TransplantationBone Marrow TransplantationHematologic NeoplasmsLiver TransplantationMyeloablative AgonistsPeripheral Blood Stem Cell TransplantationWhole-Body IrradiationTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsGraft SurvivalTissue DonorsTransplantation ChimeraKidney TransplantationUnrelated DonorsMultiple MyelomaCombined Modality TherapyHistocompatibility TestingRecurrenceHematopoietic Stem CellsCell TransplantationSurvival AnalysisDisease-Free SurvivalHistocompatibilityBusulfanRetrospective StudiesCord Blood Stem Cell TransplantationGraft vs Tumor EffectSurvival RateCyclophosphamideRemission InductionImmunosuppressive AgentsHeart TransplantationLymphoma, Non-HodgkinHematopoietic Stem Cell MobilizationMelphalanLeukemia, Myeloid, AcuteVidarabineLeukemiaGraft RejectionLung TransplantationSalvage TherapyTime FactorsTransplantation ImmunologyTransplantationAntigens, CD34Follow-Up StudiesSiblingsMyelodysplastic SyndromesHLA AntigensChimerismDonor SelectionGraft vs Leukemia EffectOrgan TransplantationHodgkin DiseaseHematopoiesisAntineoplastic AgentsPrognosisGranulocyte Colony-Stimulating FactorCarmustineEtoposideIslets of Langerhans TransplantationLiving DonorsHematologic DiseasesChemotherapy, AdjuvantPancreas TransplantationBone Marrow PurgingImmunosuppressionCyclosporinePrecursor Cell Lymphoblastic Leukemia-LymphomaBone Marrow CellsLeukapheresisAcute DiseaseMycophenolic AcidCytarabineDirected Tissue DonationLymphomaSurvivorsTransplantation, IsogeneicRisk FactorsNeoplasm, ResidualBone MarrowT-LymphocytesAntilymphocyte SerumLymphocyte TransfusionProspective StudiesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveDoxorubicinMesenchymal Stem Cell TransplantationAnemia, AplasticHepatic Veno-Occlusive DiseaseAllograftsCytomegalovirus InfectionsNeoplasm Recurrence, LocalAntibodies, MonoclonalMinor Histocompatibility Antigens